Tissue Repair After Heart Attack Aimed With Regenerative Hydrogel Developed in Argentina
핵심 요약
- 1. Argentine researchers have developed a hydrogel with regenerative properties to repair damaged tissue after a heart attack.
- 2. The technology is currently being tested on sheep, and the first human trials are planned for 2028.
- 3. Since the results obtained have not yet been published in a scientific journal, they have not passed independent verification.
- 4. Experts think the treatment could quickly integrate into Brazil and reduce the risk of heart failure.
숫자로 보기
In research conducted at an institute affiliated with Argentina's Facochoro University, a regenerative hydrogel that can repair damaged heart tissue in patients who have suffered a heart attack is being developed. Supported by a startup named Amnova Biotech and produced inspired by the human amniotic membrane, this material aims to repair damaged areas in the heart muscle, thereby reducing the risk of heart failure.
The project, led by biologist Pilar Ferrer, is currently in the preclinical trial phase on sheep. Following the completion of tests on animals, which are preferred because their heart anatomy and physiology resemble those of humans, human trials are planned to begin in 2028. However, the findings obtained so far have not yet been published in an independent peer-reviewed scientific journal.
Experts consider the study an important step in the field of tissue regeneration in medicine. Brazilian cardiovascular surgeon Edmo Atique Gabriel states that thanks to the geographical proximity between the countries, this treatment method could quickly reach Brazil and other neighboring countries.
반응 남기기
이 기사에 대해 질문
답변은 이 기사만을 바탕으로 AI가 생성합니다.
자주 묻는 질문
- 1. Q: How exactly does this new heart treatment work?
- A: The hydrogel, developed inspired by the human amniotic membrane, protects the heart fibers damaged by a heart attack, preventing the affected area from expanding and helping tissue repair.
- 2. Q: When will the treatment be tested on humans?
- A: The project is currently in the animal (sheep) testing phase, and the first human clinical trials are planned to be conducted in 2028.
- 3. Q: Will this new method be available in Brazil?
- A: Brazilian experts foresee that access to this treatment could be rapid due to the country's geographical proximity to Argentina and the ease of joint collaboration.